Bio Details

Bassil Dahiyat, Ph.D. has served as a member of our board of directors since June 2018. Dr. Dahiyat is the co-founder of Xencor (NASDAQ: XNCR), a biopharmaceutical company, and has been its President and Chief Executive Officer since the Company’s incorporation in August 1997. Dr. Dahiyat is a co-inventor of Xencor’s breakthrough XmAb® antibody engineering technology. He has led Xencor in raising over $700 million in public and private financing, creating a diverse portfolio of monoclonal antibody clinical programs for the treatment of life-threatening and debilitating diseases and establishing alliances with leading biopharmaceutical companies that generated over $200 million in upfront payments. Dr. Dahiyat holds a Ph.D. in Chemistry from Caltech and B.S. and M.S.E. degrees in Biomedical Engineering from the Johns Hopkins University. He has co-authored numerous scientific papers in the fields of protein design and drug delivery, is an inventor of 33 US and numerous foreign patents and has received scientific awards from the American Chemical Society, the Controlled Release Society, the Protein Society and Caltech.